Table 1.

Medication treatment of OUD by year

Year	Total OUD person- months	Injectable naltrexone		Oral naltrexone		Sublingual or oromucosal buprenorphine/naloxone		Sublingual buprenorphine		Transdermal buprenorphine*		Total Prescribed months /total OUD person months
		Prescribed mo.	% of total	Prescribed mo.	% of total	Prescribed mo.	% of total	Prescribed mo.	% of total	Prescribed mo.	% of total
2010	411,936	195	0.2%	1,435	1.4%	95,299	92.6%	5,966	5.8%	0	0.0%	25.0% (102,895/411,936)
2011	875,105	637	0.3%	2,929	1.6%	169,075	90.7%	12,021	6.4%	1,805	1.0%	21.3% (186,467/875,105)
2012	1,286,954	1,425	0.6%	4,041	1.6%	219,655	89.3%	17,392	7.1%	3,399	1.4%	19.1% 245,912/1,286,954)
2013	1,315,446	2,243	0.9%	4,626	1.9%	208,195	87.6%	18,612	7.8%	3,867	1.6%	18.1% (237,543/1,315,446)
2014	1,739,560	2,830	1.0%	6,144	2.2%	239,632	86.0%	24,423	8.8%	5,742	2.1%	16.0% (278,771/1,739,560)

OUD = opioid use disorder

^*Transdermal mono buprenorphine is FDA-approved for the treatment of chronic pain, not opioid use disorder.